Ketoconazole in the treatment of chronic idiopathic central serous chorioretinopathy

Catherine Meyerle, K. Bailey Freund, Pawan Bhatnagar, Viral Shah, Lawrence A. Yannuzzi

Research output: Contribution to journalArticle

Abstract

PURPOSE: To determine the effect of an adrenocorticoid antagonist (ketoconazole) in the treatment of patients with central serous chorioretinopathy (CSC). METHODS: Ketoconazole was given at an oral dose of 600 mg per day for 4 weeks. Laboratory monitoring included 24-hour urinary cortisol and liver function tests at baseline, 4 weeks, and 8 weeks. Changes in greatest linear dimension were followed with fluorescein angiography at baseline, 4 weeks, and 8 weeks. Posterior pole anatomy was assessed with optical coherence tomography at baseline, 4 weeks, and 8 weeks. Ophthalmic examination and best-corrected visual acuity were assessed at each interval visit. RESULTS: Median visual acuity in the study eye remained stable at 20/40 throughout the 8-week follow-up. Median lesion height and greatest linear dimension were stable at 4 weeks and decreased at 8 weeks. CONCLUSION: Ketoconazole lowered endogenous cortisol after 4 weeks of 600 mg daily. While median visual acuity, lesion height, and greatest linear dimension remained unchanged during the month of drug treatment, there may have been a delayed therapeutic response seen at 8 weeks.

Original languageEnglish (US)
Pages (from-to)943-946
Number of pages4
JournalRetina
Volume27
Issue number7
DOIs
StatePublished - Sep 2007
Externally publishedYes

Fingerprint

Central Serous Chorioretinopathy
Ketoconazole
Visual Acuity
Hydrocortisone
Fluorescein Angiography
Liver Function Tests
Optical Coherence Tomography
Anatomy
Therapeutics
Pharmaceutical Preparations

Keywords

  • Central serous chorioretinopathy
  • Cortisol
  • Ketoconazole
  • Steroids

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems

Cite this

Meyerle, C., Freund, K. B., Bhatnagar, P., Shah, V., & Yannuzzi, L. A. (2007). Ketoconazole in the treatment of chronic idiopathic central serous chorioretinopathy. Retina, 27(7), 943-946. https://doi.org/10.1097/IAE.0b013e318050ca69

Ketoconazole in the treatment of chronic idiopathic central serous chorioretinopathy. / Meyerle, Catherine; Freund, K. Bailey; Bhatnagar, Pawan; Shah, Viral; Yannuzzi, Lawrence A.

In: Retina, Vol. 27, No. 7, 09.2007, p. 943-946.

Research output: Contribution to journalArticle

Meyerle, C, Freund, KB, Bhatnagar, P, Shah, V & Yannuzzi, LA 2007, 'Ketoconazole in the treatment of chronic idiopathic central serous chorioretinopathy', Retina, vol. 27, no. 7, pp. 943-946. https://doi.org/10.1097/IAE.0b013e318050ca69
Meyerle, Catherine ; Freund, K. Bailey ; Bhatnagar, Pawan ; Shah, Viral ; Yannuzzi, Lawrence A. / Ketoconazole in the treatment of chronic idiopathic central serous chorioretinopathy. In: Retina. 2007 ; Vol. 27, No. 7. pp. 943-946.
@article{8acdcbcf2d004737b99c1fdf45e5646c,
title = "Ketoconazole in the treatment of chronic idiopathic central serous chorioretinopathy",
abstract = "PURPOSE: To determine the effect of an adrenocorticoid antagonist (ketoconazole) in the treatment of patients with central serous chorioretinopathy (CSC). METHODS: Ketoconazole was given at an oral dose of 600 mg per day for 4 weeks. Laboratory monitoring included 24-hour urinary cortisol and liver function tests at baseline, 4 weeks, and 8 weeks. Changes in greatest linear dimension were followed with fluorescein angiography at baseline, 4 weeks, and 8 weeks. Posterior pole anatomy was assessed with optical coherence tomography at baseline, 4 weeks, and 8 weeks. Ophthalmic examination and best-corrected visual acuity were assessed at each interval visit. RESULTS: Median visual acuity in the study eye remained stable at 20/40 throughout the 8-week follow-up. Median lesion height and greatest linear dimension were stable at 4 weeks and decreased at 8 weeks. CONCLUSION: Ketoconazole lowered endogenous cortisol after 4 weeks of 600 mg daily. While median visual acuity, lesion height, and greatest linear dimension remained unchanged during the month of drug treatment, there may have been a delayed therapeutic response seen at 8 weeks.",
keywords = "Central serous chorioretinopathy, Cortisol, Ketoconazole, Steroids",
author = "Catherine Meyerle and Freund, {K. Bailey} and Pawan Bhatnagar and Viral Shah and Yannuzzi, {Lawrence A.}",
year = "2007",
month = "9",
doi = "10.1097/IAE.0b013e318050ca69",
language = "English (US)",
volume = "27",
pages = "943--946",
journal = "Retina",
issn = "0275-004X",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Ketoconazole in the treatment of chronic idiopathic central serous chorioretinopathy

AU - Meyerle, Catherine

AU - Freund, K. Bailey

AU - Bhatnagar, Pawan

AU - Shah, Viral

AU - Yannuzzi, Lawrence A.

PY - 2007/9

Y1 - 2007/9

N2 - PURPOSE: To determine the effect of an adrenocorticoid antagonist (ketoconazole) in the treatment of patients with central serous chorioretinopathy (CSC). METHODS: Ketoconazole was given at an oral dose of 600 mg per day for 4 weeks. Laboratory monitoring included 24-hour urinary cortisol and liver function tests at baseline, 4 weeks, and 8 weeks. Changes in greatest linear dimension were followed with fluorescein angiography at baseline, 4 weeks, and 8 weeks. Posterior pole anatomy was assessed with optical coherence tomography at baseline, 4 weeks, and 8 weeks. Ophthalmic examination and best-corrected visual acuity were assessed at each interval visit. RESULTS: Median visual acuity in the study eye remained stable at 20/40 throughout the 8-week follow-up. Median lesion height and greatest linear dimension were stable at 4 weeks and decreased at 8 weeks. CONCLUSION: Ketoconazole lowered endogenous cortisol after 4 weeks of 600 mg daily. While median visual acuity, lesion height, and greatest linear dimension remained unchanged during the month of drug treatment, there may have been a delayed therapeutic response seen at 8 weeks.

AB - PURPOSE: To determine the effect of an adrenocorticoid antagonist (ketoconazole) in the treatment of patients with central serous chorioretinopathy (CSC). METHODS: Ketoconazole was given at an oral dose of 600 mg per day for 4 weeks. Laboratory monitoring included 24-hour urinary cortisol and liver function tests at baseline, 4 weeks, and 8 weeks. Changes in greatest linear dimension were followed with fluorescein angiography at baseline, 4 weeks, and 8 weeks. Posterior pole anatomy was assessed with optical coherence tomography at baseline, 4 weeks, and 8 weeks. Ophthalmic examination and best-corrected visual acuity were assessed at each interval visit. RESULTS: Median visual acuity in the study eye remained stable at 20/40 throughout the 8-week follow-up. Median lesion height and greatest linear dimension were stable at 4 weeks and decreased at 8 weeks. CONCLUSION: Ketoconazole lowered endogenous cortisol after 4 weeks of 600 mg daily. While median visual acuity, lesion height, and greatest linear dimension remained unchanged during the month of drug treatment, there may have been a delayed therapeutic response seen at 8 weeks.

KW - Central serous chorioretinopathy

KW - Cortisol

KW - Ketoconazole

KW - Steroids

UR - http://www.scopus.com/inward/record.url?scp=34748827379&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34748827379&partnerID=8YFLogxK

U2 - 10.1097/IAE.0b013e318050ca69

DO - 10.1097/IAE.0b013e318050ca69

M3 - Article

C2 - 17891021

AN - SCOPUS:34748827379

VL - 27

SP - 943

EP - 946

JO - Retina

JF - Retina

SN - 0275-004X

IS - 7

ER -